First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3671-3680

  Sessa, Cristiana ^a   Shapiro, Geoffrey I ^c   Bhalla, Kapil N ^d   Britten, Carolyn ^e   Jacks, Karen S ^f   Mita, Monica ^g   Papadimitrakopoulou, Vali ^h   Pluard, Tim ⁱ   Samuel, Thomas A ^j   Akimov, Mikhail ^b   Quadt, Cornelia ^b   Fernandez Ibarra, Cristina ^b   Lu, Hong ^b   Bailey, Stuart ^b   Chica, Sandra ^b   Banerji, Udai ^k  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NEVADA CANCER INSTITUTE   (United States)

^g University of Texas Health Science Center at San Antonio   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j MEDICAL COLLEGE OF GEORGIA   (United States)

^k ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEAT SHOCK PROTEIN 70; LOPERAMIDE; LUMINESPIB; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; ISOXAZOLE DERIVATIVE; RESORCINOL DERIVATIVE;

ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLURRED VISION; BREAST CANCER; COLON CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEART ATRIUM FLUTTER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC REGULATION; NAUSEA; NIGHT BLINDNESS; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; RECOMMENDED DRUG DOSE; SOLID TUMOR; STOMACH CANCER; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; RESORCINOLS; TREATMENT OUTCOME;

EID: 84879859752     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3404     Document Type: Article

References (39)

1. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15:9-14.
2. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer 2009;100:1523-9.
3. Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 2006;1:279- 84.
4. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64-76.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646 -74.
6. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-53. (Pubitemid 351429015)
7. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005;65:6401-8. (Pubitemid 40994428)
8. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, et al. Inhibitors of HSP90 block p95-HER2 signaling in trastuzumab-resistant tumors and suppress their growth.Oncogene 2010;29:325-34.
9. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011;17:5132-9.
10. Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res 2000;60:2090-4. (Pubitemid 30225164)
11. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005;10:86-103. (Pubitemid 40942470)
12. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67:2932-7. (Pubitemid 46724827)
13. Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE 2008;3:e0001722.
14. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87. (Pubitemid 46202262)
15. Grem JL, Morrison G, Guo XD,Agnew E, Takimoto CH, Thomas R, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93. (Pubitemid 46211366)
16. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61. (Pubitemid 46211321)
17. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
18. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51:196-218.
19. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60. (Pubitemid 351556284)
20. Jensen MR, Ide S, Brueggen J, Schoepfer J, Wang X, Quadt C, et al. Pharmacokinetic/pharmacodynamic relationship of the HSP90 inhibitor NVP-AUY922 in human xenografts and patients in a clinical phase I trial. Proc Am Assoc Cancer Res 2009; abstr 5649.
21. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008;10:R33.
22. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9:1219-33.
23. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998;17:1103-20. (Pubitemid 28221028)
24. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 1999;35:1773-82. (Pubitemid 29512308)
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
26. Gao Z, Garcia-Echeverria C, Jensen MR. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel 2010;13:193-202.
27. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012;1823:742-55
28. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly de fined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60.
29. ModiS,StopeckAT,GordonMS,MendelsonD,SolitDB,BagatellR, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7.
30. DemetriGD, LeCesne A,VonMehren M,Chmielowski B,Bauer S,Chow WA, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. ASCO Gastrointestinal Cancers Symposium 2010; abstr 64.
31. Cleary JM, Heath EI, Kwak EL, Dezube BJ, Gandhi L, Zack C, et al. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors. J Clin Oncol 2010;28 (15 suppl): abstr 3083.
32. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011;17:1561-70.
33. Shapiro G, Kwak EL, Dezube BJ, Lawrence DP, Cleary JM, Lewis S, et al. Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors. J Clin Oncol 2010;28(15 suppl): abstr 3069.
34. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011;17:6831-9.
35. Zhou D, Liu Y, Ye J, Ying W, Zhang S, Ogawa LS, et al. A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats. Mol Cancer Ther 2011;10(1 suppl): abstr C212.
36. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009;8:949-57.
37. Yap TA, Sandhu SK,Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10:514- 23.
38. Schroder CP, Pedersen JV, Chua S, Swanton C, Akimov M, Ide S, et al. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer. J Clin Oncol 2011;29(suppl): abstr e11024.
39. Garon EB, Moran T, Barlesi F, Gandhi L, Sequist LV, Kim S-W, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(suppl): abstr 7543.